Bishop 2011.

Methods	Randomised, blinded, cross‐over placebo‐controlled trial with 2‐week interventions, no washout. Measurements were taken at: ‐14; 0;14; and 28 days. Generation of allocation schedule and concealment of treatment allocation were clear. ITT analysis was used.
Participants	17 stable (monitored 2 weeks previously) adults randomised; mean (SD) age 27 years (range 19 years ‐ 67 years), mean (SD) FEV1 63 (23) % predicted (range 20% ‐ 97%).
Interventions	Delivery 30 minutes before airway clearance techniques compared to delivery immediately after airway clearance. ACT= PEP or PD/percussion. Dornase alfa naive.
Outcomes	FEV1, FVC, QOL (CFQ, VAS for well‐being, cough, sputum volume, ease of clearance). 24 hr wet sputum weight, VO2max (10 or 20 minute shuttle), adherence (diary), adverse events.
Notes	Additional data from authors, manuscript pending publication (Bishop 2011). PEDro 9/10 (Eligibility criteria: yes; random allocation: yes; concealed allocation: yes; baseline comparability: yes; blind participants: yes; blind therapists: yes; blind assessors: yes; adequate follow‐up: yes; ITT analysis: yes; between‐group comparisons: yes; point estimates and variability: no).
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Block randomisation by an independent was used.
Allocation concealment (selection bias)	Low risk	Independent distant pharmacy.
Blinding (performance bias and detection bias) All outcomes	Low risk	Placebo used; participants, therapists and assessors blinded.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Raw data available.
Selective reporting (reporting bias)	Low risk	QOL, 24 hr wet sputum weight, VO2max, adherence and adverse events were reported as non‐significant in the publication but data were not provided by authors.